ArticleNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2013
Rimonabant precipitates anxiety in rats withdrawn from palatable food: role of the central amygdala.
Article in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.
- Modulating the endocannabinoid system in alcohol use disorder: A translational systematic review and meta-analysis of preclinical and human studies.Molecular psychiatry · 2026Pooled it
- Central amygdalaNeurobiology of stress · 2026Article
- Impacts of chronic intermittent ethanol vapor and predator odor on ethanol intake and striatal DFrontiers in neuroscience · 2025Article
- The role of motivation in eating disorders: understanding sex differences in the circuits.Frontiers in behavioral neuroscience · 2025Review
- Interfering with reconsolidation by rimonabant results in blockade of heroin-associated memory.Frontiers in pharmacology · 2024Article
- Linking drug and food addiction: an overview of the shared neural circuits and behavioral phenotype.Frontiers in behavioral neuroscience · 2023Review
- Rational drug design of CB2 receptor ligands: from 2012 to 2021.RSC advances · 2022Review
- Corticotropin-releasing factor system in the lateral septum: Implications in the pathophysiology of obesity.Frontiers in molecular neuroscience · 2022Review
- Obesity as a Condition Determined by Food Addiction: Should Brain Endocannabinoid System Alterations Be the Cause and Its Modulation the Solution?Pharmaceuticals (Basel, Switzerland) · 2021Review
- Converging vulnerability factors for compulsive food and drug use.Neuropharmacology · 2021Review
- Delineation of an insula-BNST circuit engaged by struggling behavior that regulates avoidance in mice.Nature communications · 2021Article
- Review
- Consummatory, Feeding Microstructural, and Metabolic Effects Induced by Limiting Access to Either a High-Sucrose or a High-Fat Diet.Nutrients · 2020Article
- Article
- Reward sensitivity deficits in a rat model of compulsive eating behavior.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2020Article
- Endocannabinoid Signaling in the Central Amygdala and Bed Nucleus of the Stria Terminalis: Implications for the Pathophysiology and Treatment of Alcohol Use Disorder.Alcoholism, clinical and experimental research · 2019Review
- Article
- Effects of repeated long-term psychosocial stress and acute cannabinoid exposure on mouse corticostriatal circuitries: Implications for neuropsychiatric disorders.CNS neuroscience & therapeutics · 2018Article
- Neuropharmacology of compulsive eating.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2018Review
- Trace Amine Associated Receptor 1 (TAAR1) Modulation of Food Reward.Frontiers in pharmacology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 7 institutions in 2 countries.
Funding
Abstract
The anti-obesity medication rimonabant, an antagonist of cannabinoid type-1 (CB(1)) receptor, was withdrawn from the market because of adverse psychiatric side effects, including a negative affective state. We investigated whether rimonabant precipitates a negative emotional state in rats withdrawn from palatable food cycling. The effects of systemic administration of rimonabant on anxiety-like behavior, food intake, body weight, and adrenocortical activation were assessed in female rats during withdrawal from chronic palatable diet cycling. The levels of the endocannabinoids, anandamide and 2-arachidonoylglycerol (2-AG), and the CB(1) receptor mRNA and the protein in the central nucleus of the amygdala (CeA) were also investigated. Finally, the effects of microinfusion of rimonabant in the CeA on anxiety-like behavior, and food intake were assessed. Systemic administration of rimonabant precipitated anxiety-like behavior and anorexia of the regular chow diet in rats withdrawn from palatable diet cycling, independently from the degree of adrenocortical activation. These behavioral observations were accompanied by increased 2-AG, CB(1) receptor mRNA, and protein levels selectively in the CeA. Finally, rimonabant, microinfused directly into the CeA, precipitated anxiety-like behavior and anorexia. Our data show that (i) the 2-AG-CB(1) receptor system within the CeA is recruited during abstinence from palatable diet cycling as a compensatory mechanism to dampen anxiety, and (ii) rimonabant precipitates a negative emotional state by blocking the beneficial heightened 2-AG-CB(1) receptor signaling in this brain area. These findings help elucidate the link between compulsive eating and anxiety, and it will be valuable to develop better pharmacological treatments for eating disorders and obesity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.